Certara
Certara is recorded as a service provider in 50 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 50 trials · Latest update first
An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder
Sponsor Grin Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Sponsor Grifols Therapeutics LLC
- Start (EU)
- Latest update
- Estimated end
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants with Dravet Syndrome (ARGUS Trial)
Sponsor Epygenix Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (FORTIFI-HN01).
Sponsor Bicara Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Prospective, Randomized, Open-label Efficacy and Safety Study of Intravenous Brincidofovir versus Intravenous Cidofovir for Treatment of Adenovirus Infection in Pediatric and Adult Subjects After Allogeneic Hematopoietic Cell Transplantation (allo HCT)
Sponsor Symbio Pharmaceuticals Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE
Sponsor Astria Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Significant Extravascular Hemolysis
Sponsor Alexion Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome
Sponsor Epygenix Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
IB1001-304: Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study
Sponsor Intrabio Limited
- Start (EU)
- Latest update
- Estimated end
An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).
Sponsor Grifols Therapeutics LLC
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency–Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib and tislelizumab in patients with advanced/metastatic colorectal cancer
Sponsor Oncomatryx Biopharma S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
Sponsor Bial R&D Investments S.A.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The study screened and enrolled 1,048 participants in genetic-screening Part A versus an estimate of up to 3,750 needed to randomize approximately 237 participants, and randomized 272 participants.
- The trial operated at 86 sites across 11 countries, including 44 sites in nine European countries.
- Among randomized participants, 230 (84.6%) completed dosing, and treatment exposure and compliance were high, comparable between groups, and stable throughout the study.
These findings describe the trial, not the service provider’s performance or responsibility.
J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
An open-label extension study to evaluate rozanolixizumab in pediatric study participants with generalized myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Certara?
The 2026-10-09 snapshot links Certara to 50 distinct CTIS trials. Recorded services include Laboratory services, Medical writing, Statistical analysis, Clinical Metadata Repository, among 27 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Certara?
The most frequently recorded therapeutic areas are Neurology, Immunology, Genetic and Congenital Disorders, Haematological Malignancies. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Certara conducted?
The linked trials record locations in 21 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Certara delivered services.
What can this page tell me about Certara's trial experience?
Browse 50 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 5 recorded name variants under Certara. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- CERTARA
- Certara INC
- Certara Netherlands B.V.
- Certara UK Limited
- Certara USA Inc.